MERS coronavirus outbreak: Implications for emerging viral infections

Diagnostic Microbiology and Infectious Disease

Volumn 93, Issue 3, 2019, Pages 265-285

  Al Omari, Awad ^a   Rabaan, Ali A ^b   Salih, Samer ^c   Al Tawfiq, Jaffar A ^b,d   Memish, Ziad A ^e  

^a ALFAISAL UNIVERSITY   (Saudi Arabia)

^b DHAHRAN HEALTH CENTER   (Saudi Arabia)

^c DrSulaiman Al Habib Medical Group ^*  (Saudi Arabia)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ALFAISAL UNIVERSITY   (Saudi Arabia)

Author keywords

Coronavirus; Infection; MERS; Middle East; Respiratory; Saudi Arabia; Transmission

Indexed keywords

DPP4 RECEPTOR; INTERFERON; RECEPTOR; SEVERE ACUTE RESPIRATORY SYNDROME VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS RNA; ANTIVIRUS AGENT; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN DETECTION; BAT; CAMEL; CLINICAL FEATURE; EPIDEMIC; GENOMICS; HUMAN; INCUBATION TIME; INFECTION CONTROL; INFECTION PREVENTION; INNATE IMMUNITY; LABORATORY TEST; MIDDLE EAST RESPIRATORY SYNDROME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SAUDI ARABIA; VACCINATION; VIROLOGY; VIRUS CARRIER; VIRUS CLASSIFICATION; VIRUS DETECTION; VIRUS PATHOGENESIS; VIRUS TRANSMISSION; ANIMAL; COMMUNICABLE DISEASE; CORONAVIRUS INFECTION; IMMUNOLOGY; TRANSMISSION; ZOONOSIS;

ANIMALS; ANTIVIRAL AGENTS; COMMUNICABLE DISEASES, EMERGING; CORONAVIRUS INFECTIONS; DISEASE OUTBREAKS; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; SAUDI ARABIA; VIRAL VACCINES; ZOONOSES;

EID: 85055975622     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2018.10.011     Document Type: Review

References (249)

1. About SAVE LIVES: Clean Your Hands. My 5 Moments for Hand Hygiene, 2018, World Health Organization (WHO) [cited 2018 September 27]. Available from http://www.who.int/gpsc/5may/background/5moments/en/.
2. Agrawal, A.S., Ying, T., Tao, X., et al. Passive transfer of a germline-like neutralizing human monoclonal antibody protects transgenic mice against lethal Middle East respiratory syndrome coronavirus infection. Sci Rep, 6, 2016, 31629.
3. Ahmed, A.E., Estimating survival rates in MERS-CoV patients 14 and 45 days after experiencing symptoms and determining the differences in survival rates by demographic data, disease characteristics and regions: a worldwide study. Epidemiol Infect 146:4 (2018), 489–495.
4. Al Johani, S., Hajeer, A.H., MERS-CoV diagnosis: an update. J Infect Public Health 9 (2016), 216–219.
5. Alharbi, N.K., Padron-Regalado, E., Thompson, C.P., Kupke, A., Wells, D., Sloan, M.A., et al. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. Vaccine 35:30 (2017), 3780–3788.
6. Alhetheel, A., Altalhi, H., Albarrag, A., Shakoor, Z., Mohamed, D., El-Hazmi, M., et al. Assessing the detection of Middle East respiratory syndrome coronavirus IgG in suspected and proven cases of Middle East respiratory syndrome coronavirus infection. Viral Immunol 30:9 (2017), 649–653.
7. Ali, M., El-Shesheny, R., Kandeil, A., Shehata, M., Elsokary, B., Gomaa, M., et al. Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016. Euro Surveill 22:11 (2017), 1560–7917.
8. Ali, M., El-Shesheny, R., Kandeil, A., et al. Cross-sectional surveillance of Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels and other mammals in Egypt, August 2015 to January 2016. Euro Surveill 22:11 (2017), 1560–7917.
9. Almekhlafi, G.A., Albarrak, M.M., Mandourah, Y., Hassan, S., Alwan, A., Abudayah, A., et al. Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. Crit Care, 20, 2016, 123, 10.1186/s13054-016-1303-8.
10. Al-Qahtani, A., Lyroni, K., Aznaourova, M., Tseliou, M., Al-Anazi, M., Al-Ahdal, M., et al. Middle East respiratory syndrome coronavirus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ. Oncotarget 8:6 (2017), 9053–9066.
11. Alraddadi, B., Bawareth, N., Omar, H., et al. Patient characteristics infected with Middle East respiratory syndrome coronavirus infection in a tertiary hospital. Ann Thorac Med 11:2 (2016), 128–131.
12. Alraddadi, B.M., Watson, J.T., Almarashi, A., Abedi, G.R., Turkistani, A., Sadran, M., et al. Risk factors for primary Middle East respiratory syndrome coronavirus illness in humans, Saudi Arabia, 2014. Emerg Infect Dis 22:1 (2016), 49–55.
13. Alsaad, K.O., Hajeer, A.H., Al Balwi, M., Al Moaiqel, M., Al Oudah, N., Al Ajlan, A., et al. Histopathology of Middle East respiratory syndrome coronovirus (MERS-CoV) infection - clinicopathological and ultrastructural study. Histopathology 72:3 (2018), 516–524.
14. Al-Tawfiq, J., Kattan, R.F., Memish, Z.A., Middle East respiratory syndrome coronavirus disease is rare in children: an update from Saudi Arabia. World J Clin Pediatr 5:4 (2016), 391–396.
15. Al-Tawfiq, J.A., Momattin, H., Dib, J., Memish, Z.A., Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. Int J Infect Dis 20 (2014), 42–46.
16. Amer, H., Alqahtani, A.S., Alzoman, H., Aljerian, N., Memish, Z.A., Unusual presentation of Middle East respiratory syndrome coronavirus leading to a large outbreak in Riyadh during 2017. Am J Infect Control 46:9 (2018), 1022–1025.
17. Arabi, Y., Balkhy, H., Hajeer, A.H., Bouchama, A., Hayden, F.G., Al-Omari, A., et al. Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol. SpringerPlus 4 (2015), 709–716.
18. Arabi, Y.M., Arifi, A.A., Balkhy, H.H., Najm, H., Aldawood, A.S., Ghabashi, A., et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. Ann Intern Med 160:6 (2014), 389–397.
19. Arabi, Y.M., Mandourah, Y., Al-Hameed, F., Sindi, A.A., Almekhlafi, G.A., Hussein, M.A., et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med 197:6 (2018), 757–767.
20. Assiri, A., Abedi, G.R., Al Masri, M., Bin Saeed, A., Gerber, S.I., Watson, J.T., Middle East respiratory syndrome coronavirus infection during pregnancy: a report of 5 cases from Saudi Arabia. Clin Infect Dis 63:7 (2016), 951–953.
21. Assiri, A., Al-Tawfiq, J., Al-Rabeeah, A., Al-Rabiah, F., Al-Hajjar, S., Al-Barrak, A., et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis 13:9 (2013), 752–761.
22. Assiri, A., McGeer, A., Perl, T.M., Price, C.S., Al Rabeeah, A.A., Cummings, D.A.T., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369 (2013), 407–416, 10.1056/NEJMoa1306742.
23. Azhar, E.I., El-Kafrawy, S.A., Farraj, S.A., Hassan, A.M., Al-Saeed, M.S., Hashem, A.M., et al. Evidence for camel-to-human transmission of MERS coronavirus. NEJM 370:26 (2014), 2499–2505.
24. Badawi, A., Ryoo, S.G., Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis 49 (2016), 129–133.
25. Báez-Santos, Y.M., Mielech, A.M., Deng, X., Baker, S., Mesecar, A.D., Catalytic function and substrate specificity of the papain-like protease domain of nsp3 from the Middle East respiratory syndrome coronavirus. J Virol 88:21 (2014), 12511–12527.
26. Balkhy, H.H., Alenazi, T.H., Alshamrani, M.M., Baffoe-Bonnie, H., Al-Abdely, H.M., El-Saed, A., et al. Notes from the Field: Nosocomial Outbreak of Middle East Respiratory Syndrome in a Large Tertiary Care Hospital–Riyadh, Saudi Arabia, 2015. MMWR Morb Mortal Wkly Rep 65 (2016), 163–164, 10.15585/mmwr.mm6506a5.
27. Balkhy, H.H., Perl, T.M., Arabi, Y.M., Preventing healthcare-associated transmission of the Middle East Respiratory Syndrome (MERS): our Achilles heel. J Infect Public Health 9 (2016), 208–212.
28. Banik, G.R., Alqahtani, A.S., Booy, R., Rashid, H., Risk factors for severity and mortality in patients with MERS-CoV: Analysis of publicly available data from Saudi Arabia. Virol Sin 31:1 (2016), 81–84.
29. Batool, M., Shah, M., Patra, M.C., Yesudhas, D., Choi, S., Structural insights into the Middle East respiratory syndrome coronavirus 4a protein and its dsRNA binding mechanism. Sci Rep, 7(1), 2017, 11362.
30. Becker, W.B., McIntosh, K., Dees, J.H., Chanock, R.M., Morphogenesis of avian infectious bronchitis virus and a related human virus (strain 229E). J Virol 1 (1967), 1019–1027.
31. Bermingham, A., Chand, M.A., Brown, C.S., Aarons, E., Tong, C., Langrish, C., et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro Surveill, 17(40), 2012, 20290.
32. Bhadra, S., Jiang, Y.S., Kumar, M.R., Johnson, R.F., Hensley, L.E., Ellington, A.D., Real-time sequence-validated loop-mediated isothermal amplification assays for detection of Middle East respiratory syndrome coronavirus (MERS-CoV). PloS One, 10, 2015, e0123126.
33. Boonacker, E., Van Noorden, C.J.F., The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 82:2 (2003), 53–73.
34. Bosch, B.J., Martina, B.E., van der Zee, R., Lepault, J., Haijema, B.J., Versluis, C., et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. PNAS 101:22 (2004), 8455–8460.
35. Breban, R., Riou, J., Fontanet, A., Interhuman transmissibility of Middle East respiratory syndrome coronavirus: estimation of pandemic risk. Lancet 382:9893 (2013), 694–699.
36. Butt, T.S., Koutlakis-Barron, I., AlJumaah, S., AlThawadi, S., AlMofada, S., Infection control and prevention practices implemented to reduce transmission risk of Middle East respiratory syndrome-coronavirus in a tertiary care institution in Saudi Arabia. Am J Infect Control 44:5 (2016), 605–611.
37. Canton, J., Fehr, A.R., Fernandez-Delgado, R., Gutierrez-Alvarez, F., Sanchez-Aparicio, M., García-Sastre, A., et al. MERS-CoV 4b protein interferes with the NF-κB-dependent innate immune response during infection. PLoS Pathog 14:1 (2018), 1–25.
38. Centers for Disease Control & Prevention (CDC), CDC Laboratory Testing for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Available from: https://www.cdc.gov/coronavirus/mers/lab/lab-testing.html, 2017.
39. Cha, R., Joh, J., Jeong, I., Lee, J.Y., Shin, H., Kim, G., et al. Renal complications and their prognosis in Korean patients with Middle East respiratory syndrome-coronavirus from the central MERS-CoV designated hospital. J Korean Med Sci 30:12 (2015), 1807–1814.
40. Chan, C., Chu, H., Wang, Y., Wong, B.H., Zhao, X., Zhou, J., et al. Carcinoembryonic antigen-related cell adhesion molecule 5 is an important surface attachment factor that facilitates entry of Middle East respiratory syndrome coronavirus. J Virol 90:20 (2016), 9114–9127.
41. Chan, J.F., Choi, G.K., Tsang, A.K., Tee, K.M., Lam, H.Y., Yip, C.C., et al. Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses. J Clin Microbiol 53 (2015), 2722–2726.
42. Chan, J.F., Yao, Y., Yeung, M., Deng, W., Bao, L., Jia, L., et al. Treatment with lopinavir/ritonavir or interferon-β1b improves outcome of MERS-CoV infection in a nonhuman primate model of common marmoset. J Infect Dis 212:12 (2015), 1904–1913.
43. Chan, J.F.W., Lau, S.K.P., To, K.K.W., Cheng, V.C.C., Woo, P.C.Y., Yuen, K., Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 28:2 (2015), 465–522.
44. Chan, J.F.W., Sridhar, S., Yip, C.C.Y., Lau, S.K.P., Woo, P.C.Y., The role of laboratory diagnostics in emerging viral infections: the example of the Middle East respiratory syndrome epidemic. J Microbiol 55:3 (2017), 172–182.
45. Channappanavar, R., Lu, L., Xia, S., Du, L., Meyerholz, D.K., Perlman, S., et al. Protective effect of intranasal regimens containing peptidic Middle East respiratory syndrome coronavirus fusion inhibitor against MERS-CoV infection. J Infect Dis 212:12 (2015), 1894–1903.
46. Chen, X., Chughtai, A.A., Dyda, A., MacIntyre, C.R., Comparative epidemiology of Middle East respiratory syndrome coronavirus (MERS-CoV) in Saudi Arabia and South Korea. Emerg Microbes Infect, 6(6), 2017, e51.
47. Chen, Y., Chan, K., Kang, Y., Chen, H., Luk, H.K.H., Poon, R.W.S., et al. A sensitive and specific antigen detection assay for Middle East respiratory syndrome coronavirus. Emerg Microbes Infect 4:4 (2015), 1–5.
48. Cheng, K., Cheng, S., Chen, W., Lin, M.H., Chuang, S.J., Cheng, I.H., et al. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res 115 (2015), 9–16.
49. Cho, H., Excler, J., Kim, J.H., Yoon, I., Development of Middle East respiratory syndrome coronavirus vaccines – advances and challenges. Hum Vaccin Immunother 14:2 (2018), 304–313.
50. Choi, W.S., Kang, C., Kim, Y., Choi, J., Joh, J.S., Shin, H., et al. Clinical presentation and outcomes of Middle East respiratory syndrome in the Republic of Korea. Infect Chemother 48:2 (2016), 118–126.
51. Chu, D.K., Oladipo, J.O., Perera, R., Kuranga, S.A., Chan, S.M., Poon, L.L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Nigeria, 2015. Euro Surveill, 20(49), 2015, 10.2807/1560-7917.ES.2015.20.49.30086.
52. Chu, H., Zhou, J., Wong, B.H., Li, C., Chan, J.F., Cheng, Z., et al. Middle East respiratory syndrome coronavirus efficiently infects human primary T lymphocytes and activates the extrinsic and intrinsic apoptosis pathways. J Infect Dis 213:6 (2016), 904–914.
53. Clasman, J.R., Báez-Santos, Y.M., Mettelman, R.C., O'Brien, A., Baker, S.C., Mesecar, A.D., X-ray structure and enzymatic activity profile of a core papain-like protease of MERS coronavirus with utility for structure-based drug design. Sci Rep, 7, 2017, 40292.
54. Coleman, C.M., Liu, Y.V., Mu, H., Taylor, J.K., Massare, M., Flyer, D.C., et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine 32:26 (2014), 3169–3174.
55. Coleman, C.M., Sisk, J.M., Halasz, G., Zhong, J., Beck, S.E., Matthews, K.L., et al. CD8+ T Cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome. J Virol, 91(1), 2017, 1825-16.
56. Cong, Y., Hart, B.J., Gross, R., Zhou, H., Frieman, M., Bollinger, L., et al. MERS-CoV pathogenesis and antiviral efficacy of licensed drugs in human monocyte-derived antigen-presenting cells. PLoS One 13:3 (2018), 1–17.
57. Corman, V.M., Albarrak, A.M., Omrani, A.S., Albarrak, M.M., Farah, M.E., Almasri, M., et al. Viral shedding and antibody response in 37 patients with MERS-coronavirus infection. Clin Infect Dis 62:4 (2015), 477–483 civ951.
58. Corman, V.M., Eckerle, I., Bleicker, T., Zaki, A., Landt, O., Eschbach-Bludau, M., et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro Surveill 17:39 (2012), 1–6.
59. Corman, V.M., Ithete, N.L., Richards, L.R., Schoeman, M.C., Preiser, W., Drosten, C., et al. Rooting the phylogenetic tree of Middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat. J Virol 88:19 (2014), 11297–11303.
60. Corman, V.M., Kallies, R., Philipps, H., Göpner, G., Müller, M.A., Eckerle, I., et al. Characterization of a novel betacoronavirus related to Middle East respiratory syndrome coronavirus in European hedgehogs. J Virol 88:1 (2014), 717–724.
61. Corman, V.M., Müller, M.A., Costabel, U., Timm, J., Binger, T., Meyer, B., et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. Eurosurveill, 17, 2012, 20334.
62. Corman, V.M., Ölschläger, S., Wendtner, C.M., Drexler, J.F., Hess, M., Drosten, C., Performance and clinical validation of the RealStar MERS-CoV kit for detection of Middle East respiratory syndrome coronavirus RNA. J Clin Virol 60 (2014), 168–171.
63. Coronavirus infections. Disease outbreak news, 2017, World Health Organization (WHO), Geneva [cited 2018 April 4]. Available from http://www.who.int/csr/don/archive/disease/coronavirus_infections/en/.
64. Corti, D., Passini, N., Lanzavecchia, A., Zambon, M., Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J Infect Public Health 9:3 (2016), 231–235.
65. Cotten, M., Watson, S.J., Zumla, A.I., Makhdoom, H.Q., Palser, A.L., Ong, S.H., et al. Spread, circulation, and evolution of the Middle East respiratory syndrome coronavirus. MBio, 5(1), 2014, e01062-13.
66. Daczkowski, C.M., Dzimianski, J.V., Clasman, J.R., Goodwin, O., Mesecar, A.D., Pegan, S.D., Structural insights into the interaction of coronavirus papain-like proteases and interferon-stimulated gene product 15 from different species. J Mol Biol 429:11 (2017), 1661–1683.
67. Das, K.M., Lee, E.Y., Al Jawder, S.E., Enani, M.A., Singh, R., Skakni, L., et al. Acute Middle East respiratory syndrome coronavirus: temporal lung changes observed on the chest radiographs of 55 patients. Am J Roentgenol 205:3 (2015), W267–W274.
68. Das, K.M., Lee, E.Y., Langer, R.D., Larsson, S.G., Middle East respiratory syndrome coronavirus: what does a radiologist need to know?. Am J Roentgenol 206:6 (2016), 1193–1201.
69. van der Hoek, L., Pyrc, K., Jebbink, M.F., Vermeulen-Oost, W., Berkhout, R.J.M., Wolthers, K.C., et al. Identification of a new human coronavirus. Nat Med 10:4 (2004), 368–373.
70. van Doremalen, N., Falzarano, D., Ying, T., de Wit, E., Bushmaker, T., Feldmann, F., et al. Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets. Antiviral Res 143 (2017), 30–37.
71. van Doremalen, N., Miazgowicz, K.L., Milne-Price, S., Bushmaker, T., Robertson, S., Scott, D., et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol 88:16 (2014), 9220–9232.
72. Drexler, J.F., Corman, V.M., Drosten, C., Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res 101 (2014), 45–56.
73. Drosten, C., Muth, D., Corman, V.M., Hussain, R., Al Masri, M., HajOmar, W., et al. An observational, laboratory-based study of outbreaks of Middle East respiratory syndrome coronavirus in Jeddah and Riyadh, kingdom of Saudi Arabia, 2014. Clin Infect Dis 60 (2015), 369–377, 10.1093/cid/ciu812.
74. Drosten, C., Seilmaier, M., Corman, V.M., Hartmann, W., Scheible, G., Sack, S., et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis 13 (2013), 745–751.
75. Du, L., Kou, Z., Ma, C., Tao, X., Wang, L., Zhao, G., et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One, 8(12), 2013, e81587.
76. Du, L., Zhao, G., Yang, Y., Qiu, H., Wang, L., Kou, Z., et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 88:12 (2014), 7045–7053.
77. Durai, P., Batool, M., Shah, M., Choi, S., Middle east respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med, 47(8), 2015, e181.
78. Fagbo, S.F., Skakni, L., Chu, D.K.W., Garbati, M.A., Joseph, M., Peiris, M., et al. Molecular epidemiology of hospital outbreak of Middle East respiratory syndrome, Riyadh, Saudi Arabia, 2014. Emerg Infect Dis 21 (2015), 1981–1988, 10.3201/eid2111.150944.
79. Falzarano, D., de Wit, E., Martellaro, C., Callison, J., Munster, V.J., Feldmann, H., Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin. Sci Rep, 3, 2013, 1686.
80. Falzarano, D., de Wit, E., Rasmussen, A.L., Feldmann, F., Okumura, A., Scott, D.P., et al. Treatment with interferon-[alpha] 2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques. Nat Med 19:10 (2013), 1313–1317.
81. Farag, E.A.B.A., Reusken, C.B.E.M., Haagmans, B.L., Mohran, K.A., Stalin Raj, V., Pas, S.D., et al. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014. Infect Ecol Epidemiol, 5, 2015, 28305.
82. Food and Drug Administration, Fact sheet for health care providers: interpreting RealStar® MERS-CoV RT-PCR Kit U.S. Test Results. Available from: https://www.fda.gov/downloads/MedicalDevices/Safety/EmergencySituations/UCM455349.pdf, 2016.
83. Forni, D., Cagliani, R., Mozzi, A., Pozzoli, U., Al-Daghri, N., Clerici, M., et al. Extensive positive selection drives the evolution of nonstructural proteins in lineage C betacoronaviruses. J Virol 90:7 (2016), 3627–3639.
84. Fouchier, R.A., Hartwig, N.G., Bestebroer, T.M., Niemeyer, B., de Jong, J.C., Simon, J.H., et al. A previously undescribed coronavirus associated with respiratory disease in humans. PNAS 101 (2004), 6212–6216.
85. Fukushi, S., Fukuma, A., Kurosu, T., Watanabe, S., Shimojima, M., Shirato, K., et al. Characterization of novel monoclonal antibodies against the MERS-coronavirus spike protein and their application in species-independent antibody detection by competitive ELISA. J Virol Methods 251 (2018), 22–29.
86. Gossner, C., Danielson, N., Gervelmeyer, A., Berthe, F., Faye, B., Kaasik Aaslav, K., et al. Human-dromedary camel interactions and the risk of acquiring zoonotic Middle East respiratory syndrome coronavirus infection. Zoonoses Public Health 63:1 (2016), 1–9.
87. de Groot, R.J., Baker, S.C., Baric, R., et al. Family Coronaviridae. AMQ, King, Adams, M.J., Carstens, E.B., Lefkowitz, E.J., (eds.) Virus taxonomy: classification and nomenclature of viruses Ninth report of the International Committee on Taxonomy of Viruses, 2012, Academic Press, London (UK), 806–820.
88. de Groot, R.J., Baker, S.C., Baric, R.S., Brown, C.S., Drosten, C., Enjuanes, L., et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group. J Virol 87 (2013), 7790–7792.
89. Guery, B., Poissy, J., el Mansouf, L., Séjourné C., Ettahar, N., Lemaire, X., et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 381 (2013), 2265–2272.
90. Guo, X., Deng, Y., Chen, H., Lan, J., Wang, W., Zou, X., et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology 145:4 (2015), 476–484.
91. Gutiérrez, C., Tejedor-Junco, M., González, M., Lattwein, E., Renneker, S., Presence of antibodies but no evidence for circulation of MERS-CoV in dromedaries on the Canary Islands, 2015. Euro Surveill 20:37 (2015), 1560–7917.
92. Haagmans, B.L., Al Dhahiry, S.H.S., Reusken, C.B.E.M., Raj, V.S., Galiano, M., Myers, R., et al. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis 14:2 (2014), 140–145.
93. Hagemeijer, M.C., Rottier, P.J., de Haan, C.A., Biogenesis and dynamics of the coronavirus replicative structures. Viruses 4 (2012), 3245–3269.
94. Hamre, D., Procknow, J.J., A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 121 (1966), 190–193.
95. Hasley, P.B., Albaum, M.N., Li, Y.H., Fuhrman, C.R., Britton, C.A., Marrie, T.J., et al. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia?. Arch Intern Med 156:19 (1996), 2206–2212.
96. Hastings, D.L., Tokars, J.I., Abdel Aziz, I.Z., Alkhaldi, K.Z., Bensadek, A.T., Alraddadi, B.M., et al. Outbreak of Middle East respiratory syndrome at tertiary care hospital, Jeddah, Saudi Arabia, 2014. Emerg Infect Dis 22:5 (2016), 794–801.
97. Hemida, M.G., Alnaeem, A., Chu, D.K., Perera, R.A., Chan, S.M., Almathen, F., et al. Longitudinal study of Middle East respiratory syndrome coronavirus infection in dromedary camel herds in Saudi Arabia, 2014-2015. Emerg Microbes Infect, 6(6), 2017, 1.
98. Hemida, M.G., Chu, D.K.W., Poon, L.L.M., Perera, R.A.P.M., Alhammadi, M.A., Ng, H., et al. MERS coronavirus in dromedary camel herd, Saudi Arabia. Emerg Infect Dis 20:7 (2014), 1231–1234.
99. Hemida, M.G., Elmoslemany, A., Al-Hizab, F., Alnaeem, A., Almathen, F., Faye, B., et al. Dromedary camels and the transmission of Middle East respiratory syndrome coronavirus (MERS-CoV). Transbound Emerg Dis 64:2 (2017), 344–353.
100. Hemida, M.G., Perera, R.A., Wang, P., Alhammadi, M.A., Siu, L.Y., Li, M., et al. Middle East respiratory syndrome (MERS) coronavirus seroprevalence in domestic livestock in Saudi Arabia, 2010 to 2013. Euro Surveill, 18(50), 2013, 20659.
101. Hijawi, B., Abdallat, M., Sayaydeh, A., Alqasrawi, S., Haddadin, A., Jaarour, N., et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation/Infections par le nouveau coronavirus en Jordanie, avril 2012: résultats épidémiologiques d'une étude rétrospective. East Mediterr Health J 19:Suppl. 1 (2013), S12–S18.
102. Hocke, A.C., Becher, A., Knepper, J., Peter, A., Holland, G., Tönnies, M., et al. Emerging human Middle East respiratory syndrome coronavirus causes widespread infection and alveolar damage in human lungs. Am J Respir Crit Care Med 188 (2013), 882–886.
103. Houser, K.V., Gretebeck, L., Ying, T., Wang, Y., Vogel, L., Lamirande, E.W., et al. Prophylaxis with a Middle East respiratory syndrome coronavirus (MERS-CoV)-specific human monoclonal antibody protects rabbits from MERS-CoV infection. J Infect Dis 213:10 (2016), 1557–1561.
104. Hui, D.S., Azhar, E.I., Kim, Y., Memish, Z.A., Oh, M., Zumla, A., Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 18:8 (2018), e217–e227.
105. Hui, D.S.C., Lee, N., Adjunctive therapies and immunomodulating agents for severe influenza. Influenza Other Respi Viruses 7:Suppl. 3 (2013), 52–59.
106. Hung, I.F.N., To, K.K.W., Lee, C., Lee, K.L., Yan, W.W., Chan, K., et al. Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza a(H1N1) infection. Chest 144:2 (2013), 464–473.
107. Inovio, GLS-5300 SynCon® immunotherapy targeting Middle East Respiratory Syndrome. Available from http://www.inovio.com/products/infectious-disease-vaccines/mers/, 2016. (Accessed 14 June 2018)
108. Ithete, N.L., Stoffberg, S., Corman, V.M., Cottontail, V.M., Richards, L.R., Schoeman, M.C., et al. Close relative of human Middle East respiratory syndrome coronavirus in bat, South Africa. Emerg Infect Dis 19:10 (2013), 1697–1699.
109. Jiang, L., Wang, N., Zuo, T., Shi, X., Poon, K.M., Wu, Y., et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med, 6(234), 2014, 234ra59.
110. Johnson, R.F., Bagci, U., Keith, L., Tang, X., Mollura, D.J., Zeitlin, L., et al. 3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012. Virology 490 (2016), 49–58.
111. Jung, S., Kang, K.W., Lee, E., Seo, D., Kim, H., Kim, H., et al. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. Vaccine 36:24 (2018), 3468–3476.
112. Kapoor, M., Pringle, K., Kumar, A., Dearth, S., Liu, L., Lovchik, J., et al. Clinical and laboratory findings of the first imported case of Middle East respiratory syndrome coronavirus to the United States. Clin Infect Dis 59:11 (2014), 1511–1518.
113. Khalid, M., Al Rabiah, F., Khan, B., Al Mobeireek, A., Butt, T.S., Al Mutairy, E., Ribavirin and interferon-α2b as primary and preventive treatment for Middle East respiratory syndrome coronavirus: a preliminary report of two cases. Antivir Ther 20:1 (2015), 87–91.
114. Khalid, M., Khan, B., Rabiah, F.A., Alismaili, R., Saleemi, S., Rehan-Khaliq, A.M., et al. Middle eastern respiratory syndrome coronavirus (MERS CoV): case reports from a tertiary care hospital in Saudi Arabia. Ann Saudi Med 34:5 (2014), 396–400.
115. Kim, J.S., Lessons learned from new emerging infectious disease, Middle East respiratory syndrome coronavirus outbreak in Korea. Epidemiol Health 37 (2015), 1–3.
116. Kim, M.N., Ko, Y.J., Seong, M.W., Kim, J.S., Shin, B.M., Sung, H., Analytical and clinical validation of six commercial Middle East respiratory syndrome coronavirus RNA detection kits based on real-time reverse-transcription PCR. Ann Lab Med 36:5 (2016), 450–456.
117. Kim, U.J., Won, E., Kee, S., Jung, S.I., Jang, H.C., Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome. Antivir Ther 21:5 (2016), 455–459.
118. Kindler, E., Gil-Cruz, C., Spanier, J., Li, Y., Wilhelm, J., Rabouw, H.H., et al. Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. PLoS Pathog 13:2 (2017), 1–26.
119. Korea Centers for Disease Control, and Prevention, Middle East Respiratory Syndrome Coronavirus Outbreak in the Republic of Korea, 2015. Osong Public Health Res Perspect 6:4 (2015), 269–278.
120. Langenmayer, M.C., Lülf-Averhoff, A., Adam-Neumair, S., Fux, R., Sutter, G., Volz, A., Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S. Biologicals 54 (2018), 58–62.
121. Lau, S.K.P., Lau, C.C.Y., Chan, K., Li, C.P., Chen, H., Jin, D.Y., et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. J Gen Virol 94 (2013), 2679–2690.
122. Lee, J., Ahn, J.S., Yu, B.S., Cho, S.I., Kim, M.J., Choi, J.M., et al. Evaluation of a real-time reverse transcription-PCR (RT-PCR) assay for detection of Middle East respiratory syndrome coronavirus (MERS-CoV) in clinical samples from an outbreak in South Korea in 2015. J Clin Microbiol 55:8 (2017), 2554–2555.
123. Li, H.S., Kuok, D.I.T., Cheung, M.C., Ng, M.M.T., Ng, K.C., Hui, K.P.Y., et al. Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East respiratory syndrome coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model. Antiviral Res 155 (2018), 89–96.
124. Li, W., Hulswit, R.J.G., Widjaja, I., Raj, V.S., McBride, R., Peng, W., et al. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc Natl Acad Sci U S A 114:40 (2017), E8508–E8517.
125. Li, Y., Wan, Y., Liu, P., Zhao, J., Lu, G., Qi, J., et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 25:11 (2015), 1237–1249.
126. Liljander, A., Meyer, B., Jores, J., Müller, M.A., Lattwein, E., Njeru, I., et al. MERS-CoV antibodies in humans, Africa, 2013–2014. Emerg Infect Dis 22:6 (2016), 1086–1089.
127. List of Blueprint priority diseases. 2018 annual review of the Blueprint list of priority diseases, 2018, World Health Organization (WHO), Geneva, Switzerland [cited 2018 April 4]. Available from: http://www.who.int/blueprint/priority-diseases/en/.
128. Liu, R., Wang, J., Shao, Y., Wang, X., Zhang, H., Shuai, L., et al. A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization. Antiviral Res 150 (2018), 30–38.
129. Liu, S., Xiao, G., Chen, Y., He, Y., Niu, J., Escalante, C.R., et al. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors. Lancet 363:9413 (2004), 938–947.
130. Lu, G., Wang, Q., Gao, G.F., Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 23:8 (2015), 468–478.
131. Lu, L., Liu, Q., Zhu, Y., Chan, K.H., Qin, L., Li, Y., et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun, 5, 2014, 3067.
132. Lu, X., Whitaker, B., Sakthivel, S.K.K., Kamili, S., Rose, L.E., Lowe, L., et al. Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus. J Clin Microbiol 52:1 (2014), 67–75.
133. Ma, C., Li, Y., Wang, L., Zhao, G., Tao, X., Tseng, C.T., et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 32:18 (2014), 2100–2108.
134. Mackay, I.M., Arden, K.E., MERS coronavirus: diagnostics, epidemiology and transmission. Virol J, 12, 2015, 222.
135. Mailles, A., Blanckaert, K., Chaud, P., van, dW, Lina, B., Caro, V., et al. First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013. Euro Surveill 18:24 (2013), 20502–20505.
136. Mair-Jenkins, J., Saavedra-Campos, M., Baillie, J.K., Cleary, P., Khaw, F.M., Lim, W.S., et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 211:1 (2015), 80–90.
137. Malczyk, A.H., Kupke, A., Prüfer, S., Scheuplein, V.A., Hutzler, S., Kreuz, D., et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant measles virus vaccine platform. J Virol 89:22 (2015), 11654–11667.
138. Malik, A., El Masry, K.M., Ravi, M., Sayed, F., Middle East respiratory syndrome coronavirus during pregnancy, Abu Dhabi, United Arab Emirates, 2013. Emerg Infect Dis 22:3 (2016), 515–517.
139. Marra, M.A., Jones, S.J., Astell, C.R., Holt, R.A., Brooks-Wilson, A., Butterfield, Y.S., et al. The genome sequence of the SARS-associated coronavirus. Science 300 (2003), 1399–1404.
140. Matsuyama, R., Nishiura, H., Kutsuna, S., Hayakawa, K., Ohmagari, N., Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health, 16(1), 2016, 1203.
141. Matthews, K.L., Coleman, C.M., van, dM, Snijder, E.J., Frieman, M.B., The ORF4b-encoded accessory proteins of Middle East respiratory syndrome coronavirus and two related bat coronaviruses localize to the nucleus and inhibit innate immune signalling. J Gen Virol 95 (2014), 874–882.
142. Memish, Z.A., Al-Tawfiq, J., Assiri, A., AlRabiah, F.A., Al Hajjar, S., Albarrak, A., et al. Middle East respiratory syndrome coronavirus disease in children. Pediatr Infect Dis J 33:9 (2014), 904–906.
143. Memish, Z.A., Al-Tawfiq, J., Makhdoom, H.Q., Al-Rabeeah, A., Assiri, A., Alhakeem, R.F., et al. Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study. Clin Microbiol Infect 20:5 (2014), 469–474.
144. Memish, Z.A., Al-Tawfiq, J., Makhdoom, H.Q., Assiri, A., Alhakeem, R.F., Albarrak, A., et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. J Infect Dis 210:10 (2014), 1590–1594.
145. Memish, Z.A., Cotten, M., Meyer, B., Watson, S.J., Alsahafi, A.J., Al Rabeeah, A.A., et al. Human infection with MERS coronavirus after exposure to infected camels, Saudi Arabia, 2013. Emerg Infect Dis 20:6 (2014), 1012–1015.
146. Memish, Z.A., Mishra, N., Olival, K.J., Fagbo, S.F., Kapoor, V., Epstein, J.H., et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis 19:11 (2013), 1819–1823.
147. Memish, Z.A., Zumla, A.I., Al-Hakeem, R., Al-Rabeeah, A., Stephens, G.M., Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med 368:26 (2013), 2487–2494.
148. Memish, Z.A., Zumla, A.I., Assiri, A., Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med 369:9 (2013), 884–886.
149. Menachery, V.D., Gralinski, L.E., Mitchell, H.D., Dinnon, K.H., Leist, S.R., Yount, B.L., et al. Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis. mSphere 2:6 (2017), 1–12.
150. Menachery, V.D., Mitchell, H.D., Cockrell, A.S., Gralinski, L.E., Yount, B.L., Graham, R.L., et al. MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio 8:4 (2017), 665–678.
151. Menachery, V.D., Schäfer, A., Burnum-Johnson, K., Mitchell, H.D., Eisfeld, A.J., Walters, K.B., et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc Natl Acad Sci U S A 115:5 (2018), E1012–E1021.
152. Meyer, B., Drosten, C., Müller, M.A., Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res 194 (2014), 175–183.
153. Meyer, B., Müller, M.A., Corman, V.M., Reusken, C.B.E.M., Ritz, D., Godeke, G., et al. Antibodies against MERS coronavirus in dromedary camels, United Arab Emirates, 2003 and 2013. Emerg Infect Dis 20:4 (2014), 552–559.
154. Meyerholz, D.K., Lambertz, A.M., McCray, P.B., Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome. Am J Pathol 186:1 (2016), 78–86.
155. Middle East respiratory syndrome coronavirus (MERS-CoV), 2018, World Health Organization (WHO), Geneva, Switzerland [cited 2018 March 23]. Available from: http://www.who.int/emergencies/mers-cov/en/.
156. Middle East respiratory syndrome coronavirus (MERS-CoV) – Republic of Korea. Disease outbreak news, 2015, World Health Organization (WHO), Geneva October 2015. [cited 2018 April 4]. Available from http://www.who.int/csr/don/25-october-2015-mers-korea/en/ [Internet].
157. Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia. Disease outbreak news. 17 August 2017, 2017, World Health Organization (WHO), Geneva, Switzerland [cited 2018 April 4]. Available from: http://www.who.int/csr/don/17-august-2017-mers-saudi-arabia/en/.
158. Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia. Disease outbreak news. 9 October 2017, 2017, World Health Organization (WHO), Geneva, Switzerland [cited 2018 April 4]. Available from: http://www.who.int/csr/don/09-october-2017-mers-saudi-arabia/en/.
159. Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia. Disease outbreak news. 26 January 2018, 2018, World Health Organization (WHO), Geneva, Switzerland [cited 2018 April 4]. Available from: http://www.who.int/csr/don/26-january-2018-mers-saudi-arabia/en/.
160. Middle East respiratory syndrome coronavirus (MERS-CoV) Fact sheet, 2017, World Health Organization (WHO), Geneva May 2017. [cited 2018 April 19]. Available from http://www.who.int/mediacentre/factsheets/mers-cov/en/#.
161. Middle East respiratory syndrome coronavirus (MERS-CoV). Fact sheet, 2018, World Health Organization (WHO), Geneva, Switzerland [cited 2018 March 23]. Available from: http://www.who.int/mediacentre/factsheets/mers-cov/en/.
162. Millet, J.K., Whittaker, G.R., Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. PNAS 111:42 (2014), 15214–15219.
163. Modjarrad, K., Treatment strategies for Middle East respiratory syndrome coronavirus. J Virus Erad 2:1 (2016), 1–4.
164. Müller, M.A., Meyer, B., Corman, V.M., Al-Masri, M., Turkestani, A., Ritz, D., et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia: a nationwide, cross-sectional, serological study. Lancet Infect Dis 15:5 (2015), 559–564.
165. Muller, M.A., Raj, V.S., Muth, D., Meyer, B., Kallies, S., Smits, S.L., et al. Human coronavirus EMC does not require the SARS-coronavirus receptor and maintains broad replicative capability in mammalian cell lines. mBio 3 (2012), 515–519.
166. Muthumani, K., Falzarano, D., Reuschel, E.L., Tingey, C., Flingai, S., Villarreal, D.O., et al. A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med, 7(301), 2015, 301ra132.
167. Neuman, B.W., Chamberlain, P., Bowden, F., Joseph, J., Atlas of coronavirus replicase structure. Virus Res 194 (2014), 49–66.
168. Nishiura, H., Endo, A., Saitoh, M., Kinoshita, R., Kinoshita, R., Ueno, R., et al. Identifying determinants of heterogeneous transmission dynamics of the Middle East respiratory syndrome (MERS) outbreak in the Republic of Korea, 2015: a retrospective epidemiological analysis. BMJ Open, 6(2), 2016, e009936.
169. Nishiura, H., Miyamatsu, Y., Mizumoto, K., Objective determination of end of MERS outbreak, South Korea, 2015. Emerg Infect Dis 22:1 (2016), 146–148.
170. Niu, P., Zhang, S., Zhou, P., Huang, B., Deng, Y., Qin, K., et al. Ultra-potent human neutralizing antibody repertoires against MERS-CoV from a recovered patient. J Infect Dis 218 (2018), 1249–1260.
171. tenOever, B.R., The evolution of antiviral defense systems. Cell Host Microbe 19:2 (2016), 142–149.
172. Nyon, M.P., Du, L., Tseng, C.K., Seid, C.A., Pollet, J., Naceanceno, K.S., et al. Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine 36:14 (2018), 1853–1862.
173. Oboho, I.K., Tomczyk, S.M., Al-Asmari, A.M., Banjar, A.A., Al-Mugti, H., Aloraini, M.S., et al. 2014 MERS-CoV outbreak in Jeddah–a link to health care facilities. N Engl J Med 372 (2015), 846–854, 10.1056/NEJMoa1408636.
174. Oh, M., Choe, P.G., Oh, H.S., Park, W.B., Lee, S., Park, J., et al. Middle East respiratory syndrome coronavirus superspreading event involving 81 persons, Korea 2015. J Korean Med Sci 30:11 (2015), 1701–1705.
175. Ohnuma, K., Haagmans, B.L., Hatano, R., Raj, V.S., Mou, H., Iwata, S., et al. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody. J Virol 87:24 (2013), 13892–13899.
176. Omrani, A.S., Saad, M.M., Baig, K., Bahloul, A., Abdul-Matin, M., Alaidaroos, A.Y., et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis 14:11 (2014), 1090–1095.
177. Park, H.Y., Lee, E.J., Ryu, Y.A., Kim, Y., Kim, H., Lee, H., et al. Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, may to June 2015. Euro Surveill, 20(25), 2015, 21169.
178. Park, J., Jung, S., Kim, A., MERS transmission and risk factors: a systematic review. BMC Public Health, 18(1), 2018, 574.
179. Payne, D.C., Iblan, I., Alqasrawi, S., Al Nsour, M., Rha, B., Tohme, R.A., et al. Stillbirth during infection with Middle East respiratory syndrome coronavirus. J Infect Dis 209:12 (2014), 1870–1872.
180. Peck, K.M., Burch, C.L., Heise, M.T., Baric, R.S., Coronavirus host range expansion and Middle East respiratory syndrome coronavirus emergence: biochemical mechanisms and evolutionary perspectives. Ann Rev Virol 2:1 (2015), 95–117.
181. Peiris, J.S., Lai, S.T., Poon, L.L., Guan, Y., Yam, L.Y., Lim, W., et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 361 (2003), 1319–1325.
182. Perera, R.A., Wang, P., Gomaa, M.R., El-Shesheny, R., Kandeil, A., Bagato, O., et al. Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill, 18(36), 2013, 20574.
183. Qian, Z., Dominguez, S.R., Holmes, K.V., Role of the spike glycoprotein of human Middle East respiratory syndrome coronavirus (MERS-CoV) in virus entry and syncytia formation. PLoS One, 8(10), 2013, e76469.
184. Qiu, H., Sun, S., Xiao, H., Feng, J., Guo, Y., Tai, W., et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infection. Antiviral Res 132 (2016), 141–148.
185. Rabaan, A.A., Alahmed, S.H., Bazzi, A.M., Alhani, H.M., A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol 66:9 (2017), 1261–1274.
186. Rabouw, H.H., Langereis, M.A., Knaap, R.C.M., Dalebout, T.J., Canton, J., Sola, I., et al. Middle East respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress responses. PLoS Pathog 12:10 (2016), 1371–1398.
187. Raj, V.S., Mou, H., Smits, S.L., Dekkers, D.H., Müller, M.A., Dijkman, R., et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495:7440 (2013), 251–254.
188. Rambaut, A., MERS-coronavirus molecular epidemiology and genetic analysis - origin and evolution. Available at http://epidemic.bio.ed.ac.uk/coronavirus_analysis, 2014. (Accessed 14 June 2018)
189. Reusken, C.B., Ababneh, M., Raj, V.S., Meyer, B., Eljarah, A., Abutarbush, S., et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill, 18, 2013, 20662.
190. Reusken, C.B., Chrispijn Schilp, V., De Bruin, E., Kohl, R.H., Farag, E.A., Haagmans, B.L., et al. MERS-CoV infection of alpaca in a region where MERS-CoV is endemic. Emerg Infect Dis 22:6 (2016), 1129–1131.
191. Reusken, C.B., Messadi, L., Feyisa, A., Ularamu, H., Godeke, G.J., Danmarwa, A., et al. Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis 20:8 (2014), 1370–1374.
192. Reusken, C.B.E.M., Haagmans, B.L., Müller, M.A., Gutierrez, C., Godeke, G., Meyer, B., et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis 13:10 (2013), 859–866.
193. Rhee, J., Hong, G., Ryu, K.M., Clinical implications of 5 cases of Middle East respiratory syndrome coronavirus infection in a south Korean outbreak. Jpn J Infect Dis 69:5 (2016), 361–366.
194. Rota, P.A., Oberste, M.S., Monroe, S.S., Nix, W.A., Campagnoli, R., Icenogle, J.P., et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300 (2003), 1394–1399.
195. Saad, M., Omrani, A.S., Baig, K., Bahloul, A., Elzein, F., Matin, M.A., et al. Clinical aspects and outcomes of 70 patients with Middle East respiratory syndrome coronavirus infection: a single-center experience in Saudi Arabia. Int J Infect Dis 29 (2014), 301–306.
196. Sabir, J.S.M., Lam, T.T., Ahmed, M.M.M., Li, L., Shen, Y., Abo-Aba, S., et al. C-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science 351:6268 (2016), 81–84.
197. Saqib, M., Sieberg, A., Hussain, M.H., Mansoor, M.K., Zohaib, A., Lattwein, E., et al. Serologic evidence for MERS-CoV infection in dromedary camels, Punjab, Pakistan, 2012–2015. Emerg Infect Dis 23:3 (2017), 550–551.
198. Scheuplein, V.A., Seifried, J., Malczyk, A.H., Miller, L., Höcker, L., Vergara-Alert, J., et al. High secretion of interferons by human plasmacytoid dendritic cells upon recognition of Middle East respiratory syndrome coronavirus. J Virol 89:7 (2015), 3859–3869.
199. Schneider, W.M., Chevillotte, M.D., Rice, C.M., Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol 32 (2014), 513–545.
200. Scientific Advisory Board, Ministry of Health, Kingdom of Saudi Arabia Kingdom of Saudi Arabia, Scientific Advisory Board, Ministry of Health, Kingdom of Saudi Arabia. Infection prevention and control guidelines for the Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. 4th, 2018, (KSA): Ministry of Health, Kingdom of Saudi Arabia.
201. Seys, L.J.M., Widagdo, W., Verhamme, F.M., Kleinjan, A., Janssens, W., Joos, G.F., et al. DPP4, the Middle East respiratory syndrome coronavirus receptor, is upregulated in lungs of smokers and chronic obstructive pulmonary disease patients. Clin Infect Dis 66:1 (2018), 45–53.
202. Shalhoub, S., Farahat, F., Al-Jiffri, A., Simhairi, R., Shamma, O., Siddiqi, N., et al. IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. J Antimicrob Chemother 70:7 (2015), 2129–2132.
203. Sherbini, N., Iskandrani, A., Kharaba, A., Khalid, G., Abduljawad, M., Al-Jahdali, H., Middle East respiratory syndrome coronavirus in Al-Madinah City, Saudi Arabia: demographic, clinical and survival data. J Epidemiol Glob Health 7:1 (2017), 29–36.
204. Shirato, K., Kawase, M., Matsuyama, S., Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 87:23 (2013), 12552–12561.
205. Siu, K., Yeung, M.L., Kok, K., Yuen, K., Kew, C., Lui, P., et al. Middle East respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDA5 in the innate antiviral response. J Virol 88:9 (2014), 4866–4876.
206. Song, D., Ha, G., Serhan, W., Eltahir, Y., Yusof, M., Hashem, F., et al. Development and validation of a rapid immunochromatographic assay for detection of Middle East respiratory syndrome coronavirus antigen in dromedary camels. J Clin Microbiol 53:4 (2015), 1178–1182.
207. Spanakis, N., Tsiodras, S., Haagmans, B.L., Raj, V.S., Pontikis, K., Koutsoukou, A., et al. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen. Int J Antimicrob Agents 44:6 (2014), 528–532.
208. Stockman, L.J., Bellamy, R., Garner, P., SARS: systematic review of treatment effects. PLoS Med 3:9 (2006), 1525–1531.
209. Strayer, D.R., Dickey, R., Carter, W.A., Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans. Infect Disord Drug Targets 14:1 (2014), 37–43.
210. Sun, Y., Zhang, H., Shi, J., Zhang, Z., Gong, R., Identification of a novel inhibitor against Middle East respiratory syndrome coronavirus. Viruses 9:9 (2017), 1–12.
211. Tai, W., Wang, Y., Fett, C.A., Zhao, G., Li, F., Perlman, S., et al. Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J Virol, 91(1), 2017, e01651-16.
212. Tang, S., Ma, W., Bai, P., A novel dynamic model describing the spread of the MERS-CoV and the expression of dipeptidyl peptidase 4. Comput Math Methods Med, 2017, 2017, 5285810.
213. Tao, X., Garron, T., Agrawal, A.S., Algaissi, A., Peng, B., Wakamiya, M., et al. Characterization and demonstration of the value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol 90:1 (2016), 57–67.
214. Thabet, F., Chehab, M., Bafaqih, H., Al Mohaimeed, S., Middle East respiratory syndrome coronavirus in children. Saudi Med J 36:4 (2015), 484–486.
215. Thornbrough, J.M., Jha, B.K., Yount, B., Goldstein, S.A., Li, Y., Elliott, R., et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation. mBio 7:2 (2016), 1–12.
216. Treatment of MERS-CoV; information for clinicians. Clinical decision-making support for treatment of MERS-CoV patients, 2015, Public Health England/ISARIC, Oxford (UK) September 2015. [cited 2018 June 06]. Available from https://www.google.ie/?gws_rd=ssl#q=public+health+england+treatment+mers-cov [Internet].
217. Trivedi, S., Miao, C., Al-Abdallat, M., Haddadin, A., Alqasrawi, S., Iblan, I., et al. Inclusion of MERS-spike protein ELISA in algorithm to determine serologic evidence of MERS-CoV infection. J Med Virol 90:2 (2018), 367–371.
218. Volz, A., Kupke, A., Song, F., Jany, S., Fux, R., Shams-Eldin, H., et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol 89:16 (2015), 8651–8656.
219. Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23:8 (2013), 986–993.
220. Wang, Q., Qi, J., Yuan, Y., Xuan, Y., Han, P., Wan, Y., et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe 16:3 (2014), 328–337.
221. WHO target product profiles for MERS-CoV vaccines, 2017, World Health Organization, Geneva [cited 2018 June 13]. Available from http://www.who.int/emergencies/mers-cov/en/ [Internet].
222. Widagdo, W., Raj, V.S., Schipper, D., Kolijn, K., van Leenders, G.J.L.H., Bosch, B.J., et al. Differential expression of the Middle East respiratory syndrome coronavirus receptor in the upper respiratory tracts of humans and dromedary camels. J Virol 90:9 (2016), 4838–4842.
223. de Wilde, A.H., Jochmans, D., Posthuma, C.C., Zevenhoven-Dobbe, J.C., van Nieuwkoop, S., Bestebroer, T.M., et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother 58:8 (2014), 4875–4884.
224. de Wilde, A.H., Raj, V.S., Oudshoorn, D., Bestebroer, T.M., van Nieuwkoop, S., Limpens, R.W., et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin a or interferon-α treatment. J Gen Virol 94 (2013), 1749–1760.
225. Wong, K.T., Antonio, G.E., Hui, D.S.C., Lee, N., Yuen, E.H.Y., Wu, A., et al. Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 228:2 (2003), 401–406.
226. World Health Organization (WHO), Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection. Guide for field operations. Available from: http://www.who.int/csr/resources/publications/surveillance/CDS_EPR_ARO_2006_1.pdf, 2006.
227. World Health Organization (WHO), Laboratory testing for Middle East respiratory syndrome coronavirus interim guidance (revised). Available from: http://apps.who.int/iris/bitstream/handle/10665/259952/WHO-MERS-LAB-15.1-Rev1-2018-eng.pdf?sequence=1, 2018.
228. World Health Organization (WHO), Middle East respiratory syndrome coronavirus: case definition for reporting to WHO. Interim case definition as of 26 July 2017. Available from: http://www.who.int/csr/disease/coronavirus_infections/case_definition/en/.
229. Yamamoto, M., Matsuyama, S., Li, X., Takeda, M., Kawaguchi, Y., Inoue, J.I., et al. Identification of nafamostat as a potent inhibitor of Middle East respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay. Antimicrob Agents Chemother 60:11 (2016), 6532–6539.
230. Yang, Y., Liu, C., Du, L., Jiang, S., Shi, Z., Baric, R.S., et al. Two mutations were critical for bat-to-human transmission of Middle East respiratory syndrome coronavirus. J Virol 89:17 (2015), 9119–9123.
231. Yang, Y., Ye, F., Zhu, N., Wang, W., Deng, Y., Zhao, Z., et al. Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets. Sci Rep, 5, 2015, 17554.
232. Yang, Y., Zhang, L., Geng, H., Deng, Y., Huang, B., Guo, Y., et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 4:12 (2013), 951–961.
233. Ying, T., Du, L., Ju, T.W., Prabakaran, P., Lau, C.C., Lu, L., et al. Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol 88:14 (2014), 7796–7805.
234. Younan, M., Bornstein, S., Gluecks, I.V., MERS and the dromedary camel trade between Africa and the Middle East. Tropl Anim Health Prod 48:6 (2016), 1277–1282.
235. Yu, X., Zhang, S., Jiang, L., Cui, Y., Li, D., Wang, D., et al. Structural basis for the neutralization of MERS-CoV by a human monoclonal antibody MERS-27. Sci Rep, 5, 2015, 13133.
236. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., Osterhaus, A.D., Fouchier, R.A., Isolation of novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367 (2012), 1814–1820.
237. Zhang, N., Channappanavar, R., Ma, C., Wang, L., Tang, J., Garron, T., et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 13:2 (2016), 180–190.
238. Zhang, N., Jiang, S., Du, L., Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines 13:6 (2014), 761–774.
239. Zhang, N., Tang, J., Lu, L., Jiang, S., Du, L., Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res 202 (2015), 151–159.
240. Zhang, Z., Shen, L., Gu, X., Evolutionary dynamics of MERS-CoV: potential recombination, positive selection and transmission. Sci Rep, 6, 2016, 25049.
241. Zhao, G., Jiang, Y., Qiu, H., Gao, T., Zeng, Y., Guo, Y., et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. PLoS One 10:12 (2015), 1–14.
242. Zhao, J., Alshukairi, A.N., Baharoon, S.A., Ahmed, W.A., Bokhari, A.A., Nehdi, A.M., et al. Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol, 2(14), 2017 [pii: eaan5393].
243. Zheng, Y., Wang, Q.Y., Bioinformatics analysis on molecular mechanism of ribavirin and interferon-α in treating MERS-CoV. Chung-Hua Liu Hsing Ping Hsueh Tsa Chih 37:2 (2016), 291–293.
244. Zhou, J., Chu, H., Chan, J.F., Yuen, K., Middle East respiratory syndrome coronavirus infection: virus-host cell interactions and implications on pathogenesis. Virol J, 12, 2015, 218.
245. Zhou, J., Chu, H., Li, C., Wong, B.H., Cheng, Z., Poon, V.K., et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J Infect Dis 209:9 (2014), 1331–1342.
246. Zhou, J., Li, C., Zhao, G., Chu, H., Wang, D., Yan, H.H., et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv 3:11 (2017), 1–12.
247. Zhou, N., Pan, T., Zhang, J., Li, Q., Zhang, X., Bai, C., et al. Glycopeptide antibiotics potently inhibit cathepsin L in the late endosome/lysosome and block the entry of Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus (SARS-CoV). J Biol Chem 291:17 (2016), 9218–9232.
248. Zhou, Y., Vedantham, P., Lu, K., Agudelo, J., Carrion, R. Jr., Nunneley, J.W., et al. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res 116 (2015), 76–84.
249. Zielecki, F., Weber, M., Eickmann, M., Spiegelberg, L., Zaki, A.M., Matrosovich, M., et al. Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus. J Virol 87:9 (2013), 5300–5304.